Open AccessPharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain
Author(s) -
Jijun Xu,
Philippe Diaz,
Fanny AstrucDiaz,
Suzanne Craig,
Elizandro Muñoz,
Mohamed Naguib
Publication year - 2010
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0b013e3181e0cdaf
Subject(s) - medicine , neuropathic pain , cannabinoid , cannabinoid receptor , ligand (biochemistry) , pharmacology , anesthesia , neuroscience , receptor , antagonist , biology
Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N'-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide (MDA19), a CB2 agonist.